Bliss GVS Pharma Q3FY18

1. Revenue down 16% at Rs 195 cr
2. EBITDA up 5% at Rs 47 cr
3. OPM at 24.2% v/s 19.2%
4. PAT up 20% at Rs 24 cr v/s Rs 19 cr
5. Cost of materials down 31% at Rs 83 cr
6. Depreciation down 45% at Rs 6 cr